BioWorld Asia

Sep. 17, 2008

View Archived Issues

Blocking Heat Shock Proteins Points to More Selective Drugs

Unibioscreen Gets Up to $31M in Cancer Drug Deal with Drais

NicOx Shows Positive Data From 2nd Naproxcinod Trial

Polyplus-transfection Develops New Class of Oligonucleotides

Biomarker Data Point to Target Patients for Transgene's Vaccine

CV Therapeutics Gets $70M Up Front in Ex-U.S. Ranexa Deal

Other News To Note

Cell Medica Begins Study of CMV Transplant Therapy

LONDON - Cell Medica Ltd. has treated the first patient in a Phase III trial of a cell therapy treatment for the prevention of cytomegalovirus (CMV) infection in immunocompromised bone marrow transplant patients. (BioWorld International) Read More

HemoCORM, Alfama Align in Carbon Monoxide Deal

Today's news in brief

BioWorld

BioWorld briefs for March 9, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...